शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSEAchyut Healthcare Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 13 Aug, 2026 · 16:48 IST

Board approves Q1 FY27 unaudited results

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.1%Reaction day
₹7.07
prior close
₹7.14
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-1.2% vs market
Pharmaceuticals peers, median of 166sector-0.4%-0.7% vs sector

On the reaction day the stock moved 1.2 pts less than Nifty Microcap 250 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.3
10m
-0.3
15m
+0.4
30m
-0.8
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.1+0.1-1.2-0.4-0.7
Next day
-0.1+0.2-0.3-0.5+0.3
2d
-1.0+0.6-1.6-0.5-0.5
3d
-3.5-0.0-3.5-1.3-2.2
4d
-1.6+0.5-2.1-0.8-0.7
5d
-1.0+0.8-1.8-0.4-0.6
1w
-0.8+0.6-1.4-0.9+0.0
15d
-1.0+1.3-2.3+0.0-1.0
1m
-3.8-1.4-2.5-0.1-3.7
2m
-26.2-0.6-25.6-2.6-23.5
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board of Achyut Healthcare met on 13 August 2026 and approved unaudited financial results for the quarter ended 30 June 2026. Results were reviewed by the Audit Committee and underwent limited review by statutory auditor Doshi Doshi & Co, who issued an unmodified review report with no qualifications. The company operates in a single segment - Pharmaceuticals. Specific financial numbers were not included in the filing excerpt.

Likely market impact

Routine quarterly disclosure. Clean auditor review supports result credibility; no red flags evident from the filing.